Contact
searchSearch
HMP Global

Multiple Sclerosis

Conference Coverage
Portable Ultra-Low Field MRI Shows Promise in Multiple Sclerosis Monitoring
05/28/2026
Hannah Musick
In a study presented at CMSC 2026, portable ultra-low field magnetic resonance imaging (MRI) showed improved image quality and lesion detection after software upgrades, highlighting its potential to expand multiple sclerosis imaging access in...
In a study presented at CMSC 2026, portable ultra-low field magnetic resonance imaging (MRI) showed improved image quality and lesion detection after software upgrades, highlighting its potential to expand multiple sclerosis imaging access in...
In a study presented at CMSC...
05/28/2026
First Report Managed Care
Conference Coverage
African American Patients With Multiple Sclerosis Show Greater Neurodegeneration
05/28/2026
Hannah Musick
New research found that African American patients with multiple sclerosis (MS) experienced greater neurodegeneration, worse cognitive and motor performance, and accelerated brain aging compared with White patients despite having a shorter...
New research found that African American patients with multiple sclerosis (MS) experienced greater neurodegeneration, worse cognitive and motor performance, and accelerated brain aging compared with White patients despite having a shorter...
New research found that African...
05/28/2026
First Report Managed Care
Conference Coverage
Patient-Centered AI Monitoring Platform Shows Promise in Multiple Sclerosis Care
05/28/2026
Grace Taylor, MS, MA
A patient-centered remote therapeutic monitoring platform combining tele-exercise, wearable data, and artificial intelligence (AI)-enabled decision support improved mobility outcomes and clinician usability in people with multiple sclerosis,...
A patient-centered remote therapeutic monitoring platform combining tele-exercise, wearable data, and artificial intelligence (AI)-enabled decision support improved mobility outcomes and clinician usability in people with multiple sclerosis,...
A patient-centered remote...
05/28/2026
First Report Managed Care
Conference Coverage
Phase 3 FENtrepid Study Tests Fenebrutinib for Progressive MS Disability Progression
05/27/2026
Grace Taylor, MS, MA
The phase 3 FENtrepid trial compared fenebrutinib with ocrelizumab to determine whether Bruton tyrosine kinase inhibition can better slow disability progression in primary progressive multiple sclerosis (MS).
The phase 3 FENtrepid trial compared fenebrutinib with ocrelizumab to determine whether Bruton tyrosine kinase inhibition can better slow disability progression in primary progressive multiple sclerosis (MS).
The phase 3 FENtrepid trial...
05/27/2026
First Report Managed Care
Conference Coverage
Ocrelizumab Pregnancy Data Show No Increased Safety Signal in Multiple Sclerosis
05/27/2026
Hannah Musick
New real-world data from more than 5000 pregnancies found no increased risk of adverse pregnancy or infant outcomes among women with multiple sclerosis exposed to ocrelizumab before or during pregnancy.
New real-world data from more than 5000 pregnancies found no increased risk of adverse pregnancy or infant outcomes among women with multiple sclerosis exposed to ocrelizumab before or during pregnancy.
New real-world data from more...
05/27/2026
First Report Managed Care
News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
High-Efficacy Multiple Sclerosis Therapies Linked to Fewer Emergency Department Visits and Lower Risk
08/13/2025
Lisa Kuhns, PhD, MD
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying...
08/13/2025
First Report Managed Care
Conference Coverage
Exploring Patient Portal Messaging in MS Care: Value, Utilization, and Burnout Implications
06/03/2025
Juliet Gallagher
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become...
06/03/2025
First Report Managed Care
Conference Coverage
11-Year Data Support Sustained Efficacy and Safety of Ocrelizumab in MS
06/02/2025
Juliet Gallagher
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers...
06/02/2025
First Report Managed Care
Conference Coverage
Cladribine Tablets Show Strong Results in Patients With MS Switching from Injectable Therapies
05/29/2025
Grace Taylor, MS, MA
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that...
05/29/2025
First Report Managed Care
Industry Insights
News Conference Coverage
First Report Managed Care

Current Issue

June 2026
Volume 23
Issue 2
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use